1-1 of 1
Camille Benoist
Close
Save search
Sort by
Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Free
Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5233.
https://doi.org/10.1182/blood-2018-99-117485
Published: 2018